News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Raptor Pharmaceutical Inc. (RPTP) Release: Data Published In Journal Of Pediatrics Demonstrated That PROCYSBI® Improved Quality Of Life And Preserved Kidney Function In Cystinosis Patients


6/24/2014 8:42:10 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NOVATO, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that data from its open label extension study of delayed-release cysteamine bitartrate (PROCYSBI®) has been published in the Journal of Pediatrics [DOI: 10.1016/j.jpeds.2014.05.013]. The study demonstrated that patients with nephropathic cystinosis who took PROCYSBI for two years were able to sustain optimal cystine control in their white blood cells and preserve kidney function over the long term, and had significant improvements in social, school and total functioning based on validated quality of life measurement scales.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES